ProBiotix Health, a subsidiary of listed York biotech OptiBiotix Health, has signed an exclusive distribution agreement for Brazil.
Brazilian group, Ayalla Marketing, will distribute OptiBiotix’s cholesterol-reducing probiotic, LPLDL, as an ingredient and as four finished products: CholBiome, CholBiomeX3, CholBiomeBP and CholBiome.
According to OptiBiotix, the first order is expected within thirty days of approval of its food tech by Brazilian authorities.
The agreement is for an initial 12 months and there are “modest minimum order quantities for each product providing the company security of income and revenue growth”.
“We chose Ayalla because of its reputation and expertise in commercialising pharmaceutical and non-drug products with strong science and clinical studies in the Brazilian market,” Mikkel Hvid-Hansen, Commercial Director of ProBiotix Health said in a statement.